ZBTB1

ZBTB1 is a nuclear BTB/POZ zinc-finger transcription factor that functions both as a sequence-specific transcriptional repressor and as a determinant of genome integrity and lineage choice in replicating progenitors (PMID:21706167, PMID:22201126). As a DNA-binding regulator it occupies defined promoter/enhancer elements with context-dependent outputs: it activates ASNS transcription to sustain asparagine biosynthesis under amino-acid stress, and its loss sensitizes T-cell leukemia cells to L-asparaginase (PMID:32268116), while it represses transcription from CRE-containing reporters and directly occupies the ERα-binding site within the HER2 intron to suppress HER2 induction (PMID:21706167, PMID:32690611). Independently of its transcriptional outputs, ZBTB1 promotes translesion DNA synthesis: through its UBZ4 domain and association with KAP-1 it facilitates phospho-KAP-1 chromatin localization, RAD18 recruitment, and PCNA monoubiquitination at sites of UV damage (PMID:24657165), and in lymphoid progenitors it limits replication stress and enables efficient S-phase checkpoint activation, preventing p53-dependent apoptosis (PMID:27402700). These activities underpin a cell-intrinsic requirement for ZBTB1 in lymphoid lineage specification: it forms a complex with Lmo2 and Cbfa2t3 that co-binds the Tcf7 enhancer to maintain Notch-responsive T-lineage differentiation, with Tcf7 re-expression rescuing ZBTB1-deficient progenitors (PMID:36126774, PMID:22201126). ZBTB1 also restrains a default myeloid program in multipotent progenitors and is required for intestinal ILC3 development (PMID:27542215, PMID:28915559).

1. 2011 High

   Established ZBTB1 as a cell-intrinsic genetic requirement for T-cell development, defining it as an essential transcriptional regulator of lymphoid lineage specification rather than a dispensable factor.

   Evidence ENU mutagenesis with positional cloning, retroviral rescue, somatic reversion, and competitive bone marrow reconstitution in mice

   PMID:22201126

   Open questions at the time

   • Did not identify the direct transcriptional targets driving lineage specification
   • Molecular mechanism (DNA binding vs. genome maintenance) left unresolved
2. 2011 Medium

   Defined ZBTB1's molecular activity as a nuclear transcriptional repressor and mapped the contributing domains, providing the first biochemical framework for its function.

   Evidence Fluorescence localization, CRE-driven reporter assays in COS7 cells, and domain deletion analysis

   PMID:21706167

   Open questions at the time

   • No endogenous target genes validated
   • Reporter-based repression not linked to a physiological context
3. 2014 High

   Revealed an unexpected non-transcriptional role: ZBTB1 promotes translesion synthesis upstream of PCNA monoubiquitination, linking it to DNA damage tolerance.

   Evidence Reciprocal Co-IP with KAP-1, UBZ4 domain mutagenesis, UV survival assays, PCNA monoubiquitination and RAD18 recruitment assays, phospho-KAP-1 foci imaging

   PMID:24657165

   Open questions at the time

   • How ZBTB1 reconciles transcriptional and TLS functions is unclear
   • Structural basis of UBZ4-dependent action not resolved
4. 2016 High

   Connected the genome-maintenance function to lymphoid biology by showing ZBTB1 limits replication stress and enables S-phase checkpoint activation, while distinguishing checkpoint-dependent from checkpoint-independent developmental requirements.

   Evidence Bone marrow chimera competition, Bcl2 transgene and p53-knockout epistasis, γH2AX/DNA damage and S-phase checkpoint assays

   PMID:27402700

   Open questions at the time

   • Identity of the checkpoint-independent function at the DN3 stage not defined
   • Direct molecular targets in progenitors not mapped
5. 2016 Medium

   Showed ZBTB1 actively suppresses a default myeloid fate in multipotent progenitors, demonstrating a transcriptional lineage-gatekeeper role separate from its apoptosis-related functions.

   Evidence In vitro differentiation of Zbtb1-deficient LMPPs under lymphoid conditions with myeloid signature analysis and Bcl2/p53 epistasis

   PMID:27542215

   Open questions at the time

   • Direct repressed myeloid genes not identified
   • Single-lab in vitro system
6. 2017 Medium

   Extended the lineage requirement beyond conventional T cells to innate lymphoid cells, showing ZBTB1 is needed cell-intrinsically for NKp46+ RORγt+ ILC3 development.

   Evidence Bone marrow chimeras, OP9-DL1 co-culture, flow cytometry for T-bet/IFN-γ, and C. rodentium challenge

   PMID:28915559

   Open questions at the time

   • Transcriptional targets controlling ILC3 fate not defined
   • Mechanistic overlap with T-lineage program unknown
7. 2020 High

   Identified a metabolic gene-regulatory function: ZBTB1 directly binds the ASNS promoter to drive asparagine synthesis, defining a druggable vulnerability in T-cell leukemia.

   Evidence Amino-acid deprivation functional genomics screens, ZBTB1 knockout, ChIP at the ASNS promoter, and L-asparaginase sensitivity assays

   PMID:32268116

   Open questions at the time

   • Cofactors mediating activation vs. repression not determined
   • Whether ASNS regulation operates in non-leukemic contexts unclear
8. 2020 Medium

   Demonstrated direct promoter occupancy underlying repression of HER2 and placed ZBTB1 in a miR-23b-3p regulatory axis governing tamoxifen resistance in breast cancer.

   Evidence ChIP at the HER2 intronic ERα site, miRNA 3'UTR target validation, ZBTB1 gain/loss-of-function with HER2 readouts, and tamoxifen resistance assays in vitro and in vivo

   PMID:32690611

   Open questions at the time

   • Corepressor machinery at the HER2 locus not identified
   • Single-lab functional validation
9. 2022 High

   Resolved a mechanistic basis for T-lineage control by showing ZBTB1 forms a Lmo2–Cbfa2t3 complex at the Tcf7 enhancer that sustains Notch-responsive differentiation, with Tcf7 epistatically downstream.

   Evidence Two-step affinity purification with LC-MS/MS (Lmo2 interactome), CRISPR disruption, RNA-seq, ChIP-seq co-binding at Tcf7, and Tcf7 retroviral rescue in progenitors

   PMID:36126774

   Open questions at the time

   • Whether this complex governs the non-T lineage functions is untested
   • Mechanism by which the complex confers Notch responsiveness not detailed
10. 2023 Low

    Suggested a broader transcription-factor partnership repertoire by placing ZBTB1 in an EYA3 isoform interactome during myogenesis.

    Evidence Mass spectrometry of the EYA3 interactome with genome-wide transcriptomics and myoblast differentiation assays

    PMID:38026174

    Open questions at the time

    • ZBTB1-specific functional validation not described
    • Direct DNA targets and isoform specificity of ZBTB1 in muscle unresolved

• How ZBTB1 switches between transcriptional repression, transcriptional activation, and direct DNA-damage-tolerance functions—and what cofactors dictate each mode—remains unresolved.
• No structural model integrating the BTB/POZ, zinc-finger, and UBZ4 domains
• Genome-wide direct target catalog across cell types incomplete
• Determinants of activator-vs-repressor behavior unknown